North American Interleukin Inhibitors Market to Reach $45,240.0 Million by 2035
North American interleukin inhibitors market is driven by the rising prevalence of autoimmune and inflammatory diseases, increasing adoption of biologic therapies, and growing demand for targeted immunology treatments across the region. The market is witnessing strong growth in IL-1, IL-5, IL-6, IL-17, and IL-23 inhibitors for the treatment of arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and other chronic inflammatory conditions. In addition, increasing investments in biologics research, expanding approvals of monoclonal antibody therapies, and the presence of advanced healthcare infrastructure and major pharmaceutical companies are further accelerating market growth across North America.
Browse the full report description of “North American Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/north-american-interleukin-inhibitors-market
IL-17 inhibitor therapies segment is expected to account for a major market share in 2026
IL-17 inhibitor therapies are expected to hold a major market share in 2026, primarily due to the increasing adoption of targeted biologic treatments for autoimmune and inflammatory disorders. These therapies are widely utilized for managing chronic inflammatory diseases by selectively inhibiting interleukin-17 pathways associated with immune-mediated conditions. The positive Phase III results announced by Novartis for Cosentyx in giant cell arteritis treatment highlight the growing clinical expansion of IL-17 inhibitors beyond traditional autoimmune indications. Rising prevalence of inflammatory diseases and increasing demand for advanced biologic therapies with targeted mechanisms of action are expected to significantly support the growth of the IL-17 inhibitor therapies segment.
Biologic therapies for COPD segment is expected to account for a major market share in 2026
Biologic therapies for chronic obstructive pulmonary disease (COPD) are expected to hold a major market share in 2026 owing to the increasing focus on precision medicine and targeted immune therapies for chronic respiratory diseases. These therapies are increasingly being adopted to manage COPD patients with type-2 inflammation and severe respiratory complications that are inadequately controlled through conventional treatments. The FDA approval received by Dupixent from Sanofi and Regeneron Pharmaceuticals for COPD with type-2 inflammation reflects the growing expansion of biologic therapies into respiratory disease management. Increasing prevalence of chronic respiratory disorders and rising adoption of targeted biologics are expected to accelerate segment growth.
IL-23 inhibitor therapies segment is expected to account for a major market share in 2026
IL-23 inhibitor therapies are expected to hold a major market share in 2026 due to the increasing utilization of targeted immunology treatments for inflammatory bowel disease and autoimmune disorders. These therapies selectively inhibit interleukin-23 pathways involved in chronic inflammation and immune dysregulation, offering improved treatment outcomes for patients with moderate-to-severe inflammatory conditions. The FDA approval received by SKYRIZI from AbbVie for ulcerative colitis highlights the expanding role of IL-23 inhibitors in gastrointestinal autoimmune disease treatment. Increasing diagnosis rates of inflammatory bowel diseases and growing preference for biologic therapies are expected to significantly contribute to the growth of the IL-23 inhibitor therapies segment.
Ulcerative colitis biologic treatment segment is expected to account for a major market share in 2026
Ulcerative colitis biologic treatments are expected to hold a major market share in 2026, primarily driven by the rising prevalence of inflammatory bowel diseases and increasing demand for advanced targeted therapies with improved long-term disease management outcomes. These biologic therapies are increasingly utilized to reduce inflammation, induce remission, and improve quality of life for patients with moderate-to-severe ulcerative colitis. The FDA approval announced by Johnson & Johnson for TREMFYA in moderately to severely active ulcerative colitis reflects the growing expansion of biologic treatment options within gastroenterology therapeutics. Increasing clinical advancements in immunology and expanding regulatory approvals for targeted therapies are expected to further support the growth of the ulcerative colitis biologic treatment segment.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404